- Home
- KEN vs ARQT Comparison
KEN vs ARQT Comparison
Compare KEN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEN
- ARQT
- Stock Information
- Founded
- KEN 2014
- ARQT 2016
- Country
- KEN Singapore
- ARQT United States
- Employees
- KEN N/A
- ARQT N/A
- Industry
- KEN Electric Utilities: Central
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- KEN Utilities
- ARQT Health Care
- Exchange
- KEN Nasdaq
- ARQT Nasdaq
- Market Cap
- KEN 1.7B
- ARQT 2.0B
- IPO Year
- KEN N/A
- ARQT 2020
- Fundamental
- Price
- KEN $31.57
- ARQT $15.30
- Analyst Decision
- KEN
- ARQT Strong Buy
- Analyst Count
- KEN 0
- ARQT 6
- Target Price
- KEN N/A
- ARQT $18.80
- AVG Volume (30 Days)
- KEN 11.5K
- ARQT 2.6M
- Earning Date
- KEN 04-08-2025
- ARQT 05-13-2025
- Dividend Yield
- KEN 12.01%
- ARQT N/A
- EPS Growth
- KEN N/A
- ARQT N/A
- EPS
- KEN 3.23
- ARQT N/A
- Revenue
- KEN $742,796,000.00
- ARQT $196,542,000.00
- Revenue This Year
- KEN N/A
- ARQT $56.60
- Revenue Next Year
- KEN N/A
- ARQT $43.62
- P/E Ratio
- KEN $9.92
- ARQT N/A
- Revenue Growth
- KEN 8.29
- ARQT 229.74
- 52 Week Low
- KEN $19.63
- ARQT $6.99
- 52 Week High
- KEN $35.33
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- KEN 44.42
- ARQT 47.59
- Support Level
- KEN $31.31
- ARQT $16.27
- Resistance Level
- KEN $32.26
- ARQT $17.75
- Average True Range (ATR)
- KEN 0.67
- ARQT 1.07
- MACD
- KEN -0.20
- ARQT -0.15
- Stochastic Oscillator
- KEN 10.07
- ARQT 17.34
About KEN Kenon Holdings Ltd.
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented, businesses. The company's operating segments include OPC; CPV Group; and ZIM. It generates maximum revenue from the OPC segment. OPC operates in the Israeli electricity generation sector, including initiating, developing, constructing, and operating power plants and selling and supplying electricity. Geographically, it derives a majority of its revenue from Israel.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.